Company-reported prevalence

BIM-IOL System

Overview

Field	Value
Drug	BIM-IOL System (bimatoprost drug pad-intraocular lens system)
Indication	Open-angle glaucoma or ocular hypertension
Disease	Open-angle glaucoma (OAG) and ocular hypertension (OHT), including patients with glaucoma or OHT undergoing cataract surgery
Company	SpyGlass Pharma, Inc. (worldwide rights); patents co-owned with and exclusively licensed from the Regents of the University of Colorado
Documents searched	Corporate website, About Glaucoma, Market Opportunity, Our Technology, Study Data, and Pipeline pages (accessed October 2026); Form S-1 (January 2026); Form 10-K for 2025 (March 2026); Form 10-Q for the second quarter of 2026 (August 2026); press releases (January, March, May, August, September, and October 2026); corporate presentation (August 2026)
Data as of	October 14, 2026
Prepared by	AI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Eligible population: SpyGlass Pharma website, October 2026

“An estimated 1 million US patients with glaucoma or OHT are expected to undergo cataract surgery annually.” (opens the source at this quote in a new tab)

Cited source: 2.1 Market Scope 2025

SpyGlass Pharma (2026) website, About Glaucoma, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Eligible population: SpyGlass Pharma Form 10-K for 2025, March 2026

“We estimate that the total addressable market in the United States for the BIM-IOL System is approximately $13 billion based on the estimated one million glaucoma and OHT patients expected to undergo cataract surgery in 2025” (opens the source at this quote in a new tab)
“The same report estimates that approximately one million of these surgeries will be performed in patients with glaucoma or OHT.” (opens the source at this quote in a new tab)

Cited source: 2.1 Market Scope 2025

SpyGlass Pharma (2026) Form 10-K for 2025, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Eligible population: SpyGlass Pharma corporate presentation, August 2026

“Approximately one million glaucoma and OHT patients projected to undergo cataract surgery in the U.S. in 2025, per MarketScope 2025 Global Glaucoma Device Report.” (opens the source at this quote in a new tab)

Cited source: 2.1 Market Scope 2025

SpyGlass Pharma (2026) corporate presentation, August 2026, quoted passage highlighted — Captured from page 8 of 33 (opens in a new tab)

Eligible population: SpyGlass Pharma press release, August 2026

“We are pleased to report that enrollment in our parallel Phase 3 registrational trials of the BIM-IOL System, which if approved by the US Food and Drug Administration, has the potential to serve the approximately one million annual cataract procedures in glaucoma and ocular hypertension patients remains on track for completion in 2027.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

SpyGlass Pharma (2026) press release, second quarter 2026 results, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Prevalence (share of cataract surgery patients with glaucoma or OHT): SpyGlass Pharma website, October 2026

“Glaucoma or OHT patients represent approximately 20% of all patients who undergo cataract surgery” (opens the source at this quote in a new tab)

Cited source: 2.3 Tseng 2012; 2.2 Terveen 2022

Prevalence (share of cataract surgery patients with glaucoma or OHT): SpyGlass Pharma Form 10-K for 2025, March 2026

“approximately two-thirds of cataract surgeons in the United States do not perform MIGS procedures routinely despite an estimated 20% of their cataract patients having glaucoma or OHT according to a published research article analyzing cataract patients based on U.S. Medicare claims data” (opens the source at this quote in a new tab)

Cited source: 2.2 Terveen 2022

Europe

No evidence found.

Global

Number affected (all glaucoma): SpyGlass Pharma website, October 2026

“It affects more than an estimated 80 million people worldwide and is the second leading cause of permanent blindness worldwide.” (opens the source at this quote in a new tab)

Cited source: 2.4 Quigley 2006; 2.5 Davuluru 2023

Number affected (open-angle glaucoma): SpyGlass Pharma Form 10-K for 2025, March 2026

“According to MarketScope 2025 Global Glaucoma Device Report, over 80 million people worldwide are expected to be affected by OAG in 2025.” (opens the source at this quote in a new tab)

Cited source: 2.1 Market Scope 2025

Number affected (open-angle glaucoma): SpyGlass Pharma corporate presentation, August 2026

“Everyday, over 80 million people worldwide fight to save their sight from open angle glaucoma” (opens the source at this quote in a new tab)

Cited source: 2.1 Market Scope 2025

Number affected (ocular hypertension): SpyGlass Pharma Form 10-K for 2025, March 2026

“According to MarketScope 2025 Global Glaucoma Device Report, OHT is expected to impact more than 48 million people worldwide in 2025.” (opens the source at this quote in a new tab)

Cited source: 2.1 Market Scope 2025

Other countries and regions

Eligible population (outside the United States): SpyGlass Pharma Form 10-K for 2025, March 2026

“According to MarketScope 2025 Global Glaucoma Device Report, an estimated 5.4 million glaucoma and OHT patients are expected to undergo cataract surgeries outside of the United States in 2025.” (opens the source at this quote in a new tab)

Cited source: 2.1 Market Scope 2025

Geography not stated

Number affected (people blind from glaucoma): SpyGlass Pharma Form 10-K for 2025, March 2026

“Glaucoma is a group of chronic, progressive optic neuropathies characterized by damage to the optic nerve, ultimately leading to irreversible vision loss and, in advanced cases, permanent blindness for approximately 3.6 million individuals.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Sources the company cites

Market scope 2025

Reference as the company lists it, website, About Glaucoma

“Market Scope. 2025 Glaucoma Surgical Device Market Report. Accessed November 19, 2025.” (opens the source at this quote in a new tab)

Reference as the company lists it, Form 10-K for 2025

“MarketScope 2025 Global Glaucoma Device Report” (opens the source at this quote in a new tab)

Reference as the company lists it, corporate presentation, August 2026

“MarketScope 2025 Global Glaucoma Device Report; based on expected prevalence for 2025” (opens the source at this quote in a new tab)

Passage carrying the figure

Not quoted: A paid market research report; no public version carries the figures. The website names it the 2025 Glaucoma Surgical Device Market Report and links the address below, and the Form 10-K and the presentation name it the 2025 Global Glaucoma Device Report.

Terveen 2022

Reference as the company lists it, website, About Glaucoma

“Terveen D, Berdahl J, Dhariwal M, Meng Q. Real-world cataract surgery complications and secondary interventions incidence rates: an analysis of US Medicare Claims Database.” (opens the source at this quote in a new tab)

Reference as the company lists it, Form 10-K for 2025

“Terveen et. al, Real-World Cataract Surgery Complications and Secondary Interventions Incidence Rates: An Analysis of US Medicare Claims Database” (opens the source at this quote in a new tab)

Passage carrying the nearest figure

“133,896 records of 82,246 CMS FFS claims were included in the analysis.” (opens the source at this quote in a new tab)
“The most common comorbidities included diabetes (28.6%), glaucoma (22.1%), and macular degeneration (21.7%).” (opens the source at this quote in a new tab)

Terveen 2022, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Tseng 2012

Reference as the company lists it

“Tseng VL, Yu F, Lum F, Coleman AL. Risk of fractures following cataract surgery in Medicare beneficiaries.” (opens the source at this quote in a new tab)

Passage carrying the nearest figure

“There were 1,113,640 US Medicare beneficiaries 65 years and older with a diagnosis of cataract between 2002 and 2009 in the 5% random sample; of these patients, 410,809 (36.9%) received cataract surgery during the study period.” (opens the source at this quote in a new tab)
“The most common ocular comorbidity was glaucoma (n = 212,382; 19.1%).” (opens the source at this quote in a new tab)

Tseng 2012, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Quigley 2006

Reference as the company lists it

“Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020.” (opens the source at this quote in a new tab)

Passage carrying the nearest figure

“There will be 60.5 million people with OAG and ACG in 2010, increasing to 79.6 million by 2020, and of these, 74% will have OAG.” (opens the source at this quote in a new tab)

Quigley 2006, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Davuluru 2023

Reference as the company lists it

“Davuluru SS, Jess AT, Kim JSB, Yoo K, Nguyen V, Xu BY. Identifying, understanding, and addressing disparities in glaucoma care in the United States.” (opens the source at this quote in a new tab)

Passage carrying the figure

“Glaucoma is the leading cause of irreversible blindness worldwide, currently affecting around 80 million people.” (opens the source at this quote in a new tab)

Davuluru 2023, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Overview

1Company statements of prevalence

Eligible population: SpyGlass Pharma website, October 2026

Eligible population: SpyGlass Pharma Form 10-K for 2025, March 2026

Eligible population: SpyGlass Pharma corporate presentation, August 2026

Eligible population: SpyGlass Pharma press release, August 2026

Prevalence (share of cataract surgery patients with glaucoma or OHT): SpyGlass Pharma website, October 2026

Prevalence (share of cataract surgery patients with glaucoma or OHT): SpyGlass Pharma Form 10-K for 2025, March 2026

Number affected (all glaucoma): SpyGlass Pharma website, October 2026

Number affected (open-angle glaucoma): SpyGlass Pharma Form 10-K for 2025, March 2026

Number affected (open-angle glaucoma): SpyGlass Pharma corporate presentation, August 2026

Number affected (ocular hypertension): SpyGlass Pharma Form 10-K for 2025, March 2026

Eligible population (outside the United States): SpyGlass Pharma Form 10-K for 2025, March 2026

Number affected (people blind from glaucoma): SpyGlass Pharma Form 10-K for 2025, March 2026

2Sources the company cites

Reference as the company lists it, website, About Glaucoma

Reference as the company lists it, Form 10-K for 2025

Reference as the company lists it, corporate presentation, August 2026

Passage carrying the figure

Reference as the company lists it, website, About Glaucoma

Reference as the company lists it, Form 10-K for 2025

Passage carrying the nearest figure

Reference as the company lists it

Passage carrying the nearest figure

Reference as the company lists it

Passage carrying the nearest figure

Reference as the company lists it

Passage carrying the figure

3References

Company statements of prevalence

Sources the company cites

References